Clin Osteol 2007; 12(1): 17-20

Promising agents for treating osteoporosisGuidelines

S. Kutílek, T. Hála T.

Osteoporosis therapy is closely linked to basic research and development of new antiosteoporotic drugs is a very dynamic process. There are great expectations regarding denosumab (AMG 162), which is a human monoclonal antibody to RANKL. Denosumab is very potent in decreasing bone resorption. Another future antiosteoporotic drug seems to be glucagon-like-peptide-2 (GLP-2), which has proven a strong antiresorptive efficacy. Its effect on bone mineral density and fracture rate needs to be evaluated in further clini­ cal trials. Cathepsin K inhibitors are likely to be another group of perspective drugs to treat osteoporosis. Cathepsin K inhibitors have a significant antiresorptive activity without affecting bone formation. Their efficacy and safety also has to be asseseed in clinical trials. The principal aim of osteoporosis therapy shouldn't be a sole increase in bone mineral density but a reduction of fracture risk and an improvement in quality of life.

Keywords: osteoporosis, denosumab, glucagon-like-peptide-2, cathepsin K inhibitors

Published: June 11, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kutílek S, Hála TT. Promising agents for treating osteoporosis. Osteologický bulletin. 2007;12(1):17-20.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rosen CJ. Postmenopausal osteoporosis. N Engl J Med 2005;353:595-603. Go to original source...
    2. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: The critical need for a uni­ form nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177-84. Go to original source...
    3. Lacey DL, Timms E, Tan HL, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76. Go to original source...
    4. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5. Go to original source...
    5. Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001;7:613-35. Go to original source...
    6. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005;5:618-25. Go to original source...
    7. Hamdy NA Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep 2005;3:121-5.
    8. Dougall W, Chaisson M.Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases. Clin Calcium 2006;16:627- 35.
    9. Abrahamsen B, Teng AY. Technology evaluation: denosumab, Amgen. Curr Opin Mol Ther 2005;7:604-10.
    10. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006;6:1041-50. Go to original source...
    11. McClung MR. Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 2006;4:28-33. Go to original source...
    12. Takahashi N, Ozawa H. A new treatment for osteoporosis using fully human mo­ noclonal antibody to RANKL, AMG 162. Clin Calcium 2005;15:43-8..
    13. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Hol­ mes GB, Dunstan CR, DePaoli AM. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-66. Go to original source...
    14. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Hol­ loway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31. Go to original source...
    15. Mera T, Ito K. Therapeutic agents for disorders of bone and calcium metabolism. Denosumab: a fully human monoclocal antibodytargeting RANKL as a therapy for cancer-induced bone diseases. Clin Calcium 2007;17:37-46.
    16. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Paterson MC, Bekker PJ. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor denosumab, in patients with multiple myeloma or bone me­ tastases from breast cancer. Clin Cancer Res 2006;12:1221-8. Go to original source...
    17. Wallis K, Walters JR, Forbes A. Review article: glucagon-like peptide 2 - current applications and future directions. Aliment Pharmacol Ther 2007;25:365-72. Go to original source...
    18. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adapti­ ve response to massive intestinal resection in rat. Am J Physiol 1998;275:G911-21. Go to original source...
    19. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces che­ motherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001;61:687-93.
    20. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2004;286:G964-72. Go to original source...
    21. Wu GH, Chen J, Li H, Wu ZH. Effects of glucagon-like peptide 2 on the adapta­ tion of residual small bowel in a rat model of short bowel syndrome. Zhonghua Wei Chang Wai Ke Za Zhi 2006; 9:441-4.
    22. Washizawa N, Gu LH, Gu L, Openo KP, Jones DP, Ziegler TR. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. J Parenter Enteral Nutr 2004;28:399-409. Go to original source...
    23. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB. Glucagon-like peptide 2 im­ proves nutrient absorption and nutritional status in short-bowel patients with no colon Gastroenterology 2001;120:806-15 Go to original source...
    24. Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, GraffJ, Han­ sen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Staun M, Mortensen PB. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers ofbone turnover in short-bowel patients with no colon. Scand J Gastroenterol 2002;37:392-8. Go to original source...
    25. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henrik­ sen EE, Byrjalsen I, Krarup T, Holst JJ, Christiansen C. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003;18:2180-9. Go to original source...
    26. Henriksen DB, Alexandersen P, Byrjalsen I, Hartmann B, Bone HG, Christiansen C, Holst JJ. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004;34:140-7. Go to original source...
    27. Henriksen DB, Alexandersen P, Hartmann B, Adrian C, Byrjalsen I, Holst JJ. GLP-2 Administration Attenuates Nocturnal Bone Resorption in Postmenopausal Women: A 14-Day Study. J Bone Miner Res 2005;20 Suppl 1: CO 30.
    28. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C. Disassociation of bone resorption and formation by GLP2 A 14-day study in healthy postmenopausal women. Bone 2007;40:723-9. Go to original source...
    29. Fujita Y, Nakata K, Yasui N et al. Novel mutations of cathepsin K gene in patients with pycnodysostosis and their characterization. J Clin Endocrinol Metab 2000;85:425-31. Go to original source...
    30. Fuller K, Kirstein B, Chambers TJ. The regulation and enzymatic basis ofbone re­ sorption by human osteoclasts. Clin Sci (Lond). 2007 Jan 23; [Epub ahead of print] Go to original source...
    31. Barrett DG, Boncek VM, Catalano JG, Deaton DN, Hassell AM, Jurgensen CH, Long ST et al. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett 2005;15:3540-6. Go to original source...
    32. Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB,Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ. Acyclic, orally bioavailable ketone-based cathepsin K inhibitors. Bioorg Med Chem Lett 2007;17:22-7. Go to original source...
    33. Deaton DN, Tavares FX. Design of cathepsin K inhibitors for osteoporosis. Curr Top Med Chem 2005;5:1639-75. Go to original source...
    34. Deaton DN, Kumar S. Cathepsin K inhibitors: their potential as anti-osteoporosis agents. Progr Med Chem 2004;2: 245-375. Go to original source...
    35. Kim TS, Tasker AS. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis. Curr Top Med Chem 2006;6:355-60. Go to original source...
    36. Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH Jr, Wright LL, Zhou HQ. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin K. J Med Chem 2004;47:588-99. Go to original source...
    37. Grabowska U, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhi­ bitor design. Curr Opin Drug Discov Devel 2005;8:619-30.
    38. Turk B. Targeting proteases: successes, failures and future prospects. Nature Rev Drug Disc 2006;5: 785-99. Go to original source...
    39. Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, La­ montagne S, Masse F, Riendeau D, Toulmond S, Percival MD. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 2005;48:7535-43. Go to original source...
    40. Papanastasiou P, Ortmann CE, Ollson M, vigneron A, Trechsel U. Effect of three month treatment with the cathepsin-K inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women:Evidence for uncoupling of bone re­ sorption and bone formation. J Bone Miner Res 2006;21:Suppl 1:S59:1223.
    41. Adami S, Supronik J, Hala T, Brown JP, Garnero P, Haemmerle S, Ortmann CE, Bouisset F, Trechsel U. Effect of one year treatment with the Cathepsin-K inhibi­ tor, balicatib, in postmenopausal women with osteopenia/osteoporosis. J Bone Mi­ ner Res 2006;21:Suppl 1:S24:1085.
    42. Itabashi A, Kurata N, Sugita Y, Kawai Y. Balicatib, a novel cathepsin-K inhibitor, increases serum intact PTH beyond diurnal patterns follwing 14-daily administra­ tion in Japanese postmenopausal women. J Bone Miner Res 2006;21:Suppl 1:S24:1086.
    43. Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang SM, Tomaszek T, Yamashita DS, Marquis RW, Oh H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers ofbone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007;40:122-31. Go to original source...
    44. Park JH, Lim JI, Yang JS, Kwak WY, Sung SY, Kim HJ, Kim SH, Lee CH, Shim JY, Bae MH, Shin YA, Huh Y, Han TD, Chong W, Choi H, Ahn BN, Yang SO, Son MH. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats. J Pharmacol Exp Ther 2006;318:555-62. Go to original source...
    45. Hosking DJ, Geusens P, Rizzoli R. Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM 2005;98:403-13. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.